Enanta Pharma (ENTA) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. META
4. NFLX
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. IBM

Go back to Enanta Pharma (ENTA) Reports In-Line Q4 EPS

Enanta Pharmaceuticals (ENTA) PT Lowered to $72 at RBC Capital

November 19, 2021 6:11 AM EST

RBC Capital analyst Brian Abrahams lowered the price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $72.00 (from $74.00) while maintaining a Sector Perform rating.... More

Enanta Pharma (ENTA) is discontinuing development of EDP-721

November 18, 2021 4:11 PM EST

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced it is discontinuing development of EDP-721, an oral HBV RNA destabilizer, based on emerging safety observations in the single ascending dose part of a Phase 1 study in healthy volunteers.

Despite the clean preclinical safety profile demonstrated in comprehensive toxicology studies, safety signals were seen in healthy subjects after administration of EDP-721. Patient... More